Phytochemicals for the management of melanoma

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 12, 2016, Pages 953-979

  Pal, Harish Chandra ^a   Hunt, Katherine Marchiony ^a   Diamond, Ariana ^a   Elmets, Craig A ^a   Afaq, Farrukh ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Cell proliferation; Invasion; Melanoma; Metastasis; Phytochemicals; Signaling pathways

Indexed keywords

3 INDOLEMETHANOL; APIGENIN; B RAF KINASE; CAPSAICIN; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIGALLOCATECHIN GALLATE; FISETIN; GENISTEIN; LUTEOLIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLANT MEDICINAL PRODUCT; PROANTHOCYANIDIN; PROTEIN P16; PROTEIN P53; RESVERATROL; SILYMARIN; ANTINEOPLASTIC AGENT;

BIOAVAILABILITY; CELL PROLIFERATION; CELL SURVIVAL; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; MELANOMA; METASTATIC MELANOMA; MUTATION; ONCOGENE N RAS; REVIEW; ANIMAL; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PREVENTION AND CONTROL; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL PROLIFERATION; HUMANS; MELANOMA; MUTATION; NEOPLASM INVASIVENESS; PHYTOCHEMICALS; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS;

EID: 84983734646     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666160211120157     Document Type: Review

References (352)

1. Parra, E.J. Human pigmentation variation: evolution, genetic basis, and implications for public health. Am. J. Phys. Anthropol., 2007, Suppl 45, 85-105.
2. Rogers, H.W., Weinstock, M.A., Harris, A.R., Hinckley, M.R., Feldman, S.R.; Fleischer, A.B.; Coldiron, B.M. Incid ence estimate of nonmelanoma skin cancer in the United States, 2006. Arch. Dermatol., 2010, 146(3), 283-7.
3. Stern, R.S. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch. Dermatol., 2010, 146(3), 279-82.
4. Rogers, H.W.; Coldiron, B.M., Analysis of skin cancer treatment and costs in the United States Medicare population, 1996-2008. Dermatol. Surg., 2013, 39(1 Pt 1), 35-42.
5. Khavari, P.A. Modelling cancer in human skin tissue. Nat. Rev. Cancer, 2006, 6(4), 270-80.
6. Darr, O.A.; Colacino, J.A.; Tang, A.L.; McHugh, J.B.; Bellile, E.L.; Bradford, C.R.; Prince, M.P.; Chepeha, D.B.; Rozek, L.S.; Moyer, J.S. Epigenetic alterations in metastatic cutaneous carcinoma. Head Neck, 2014, 10.1002/hed.23701.
7. Houghton, A.N.; Polsky, D. Focus on melanoma. Cancer Cell, 2002, 2(4), 275-8.
8. Erdei, E.; Torres, S.M. A new understanding in the epidemiology of melanoma. Exp. Rev. Anticancer Ther., 2010, 10(11),1811-23.
9. Erdmann, F.; Lortet-Tieulent, J.; Schuz, J.; Zeeb, H.; Greinert, R.; Breitbart, E.W.; Bray, F. International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int. J. Cancer, 2013, 132(2), 385-400.
10. Ries LAGMDKM.; Stinchcomb, D.G; Howlader, N.; Horner, M.J.; Mariotto, A.; Miller, B.A.; Feuer, E.J.; ltekruse, S.F.; Lewis, D.R.; Clegg, L.; Eisner, M.P.; Reichman, M. SEER Cancer Statistics Review,1975–2005. 2007 [cited 2014]; Available from: http://seer.cancer.gov/archive/csr/1975_2005/.
11. R, L. Global Burden of Disease of Solar Ultraviolet Radiation. No. 13. 2006, World Health Organization.
12. Ferlay J. S.I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.B.; F. Globocan. 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013.
13. Institute, N.C. SEER Stat Fact Sheets: Melanoma of the Skin. 2014 cited 2014; Available from:http://seer.cancer.gov/statfacts/html/ melan.html.
14. Society, A.C. Cancer Facts & Figures. 2013 [cited 2014]; Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
15. DeSantis, C.E.; Lin, C.C.; Mariotto, A.B.; Siegel, R.L.; Stein, K.D.; Kramer, J.L.; Alteri, R.; Robbins, A.S.; Jemal, A. Cancer treatment and survivorship statistics. CA Cancer J. Clin., 2014, 64(4), 252-71.
16. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2015, 65(1), 5-29.
17. Clark, W.H. Tumour progression and the nature of cancer. Br. J. Cancer, 1991, 64(4), 631-44.
18. Clark, W.H. Jr. Human cutaneous malignant melanoma as a model for cancer. Cancer Metastasis. Rev., 1991, 10(2), 83-8.
19. D'Orazio, J.; Jarrett, S.; Amaro-Ortiz, A.; Scott, T. UV Radiation and the Skin. Int. J. Mol. Sci., 2013, 14(6), 12222-48.
20. Hoerter, J.D.; Bradley, P.; Casillas, A.; Chambers, D.; Denholm, C.; Johnson, K.; Weiswasser, B. Extrafollicular dermal melanocyte stem cells and melanoma. Stem Cells Int., 2012, 2012, 407079.
21. Bohm, M.; Schulte, U.; Funk, J.O.; Raghunath, M.; Behrmann, I.; Kortylewski, M.; Heinrich, P.C.; Kues, T.; Luger, T.A.; Schwarz, T. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity. J. Invest. Dermatol., 2001, 117(1), 132-40.
22. Holzel, M.; Bovier, A.; Tuting, T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat. Rev. Cancer, 2013, 13(5), 365-76.
23. Briggs, J.C. Histological diagnosis and prognosis of malignant melanoma. J. Clin. Pathol., 1980, 33(7), 702.
24. Levene, A. On the histological diagnosis and prognosis of malignant melanoma. J. Clin. Pathol., 1980, 33(2), 101-24.
25. McGovern, V.J. The nature of melanoma. A critical review. J. Cutan. Pathol., 1982, 9(2), 61-81.
26. Metcalf, J.S. Melanoma: criteria for histological diagnosis and its reporting. Semin. Oncol., 1996, 23(6), 688-92.
27. Smoller, B.R. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod. Pathol., 2006, 19 Suppl 2, S34-40.
28. Taran, J.M; Heenan, P.J. Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis. Cancer, 2001, 91(9), 1822-5.
29. Kiene, P.; Petres-Dunsche, C.; Folster-Holst, R. Pigmented pedunculated malignant melanoma. A rare variant of nodular melanoma. Br. J. Dermatol., 1995, 133(2), 300-2.
30. Plotnick, H.; Rachmaninoff, N.; VandenBerg, H.J. Jr. Polypoid melanoma: a virulent variant of nodular melanoma. Report of three cases and literature review. J. Am. Acad. Dermatol., 1990, 23(5 Pt 1), 880-4.
31. Cohen, L.M. Lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol., 1997, 36(6 Pt 1), 913.
32. Kroumpouzos, G.; Frank, E.W.; Albertini, J.G.; Krivo, J.M.; Ramsey, M.L.; Tyler, W.B.; Cohen, L.M. Lentigo maligna with spread onto oral mucosa. Arch. Dermatol., 2002, 138(9), 1216-20.
33. Chen, Y.J.; Wu, C.Y.; Chen, J.T.; Shen, J.L.; Chen, C.C.; Wang, H.C. Clinicopathologic analysis of malignant melanoma in Taiwan. J. Am. Acad. Dermatol., 1999, 41(6), 945-9.
34. King, R. Lentiginous melanoma. Arch. Pathol. Lab. Med., 2011, 135(3), 337-41.
35. King, R.; Page, R.N.; Googe, P.B.; Mihm, M.C. Jr. Lentiginous melanoma: a histologic pattern of melanoma to be distinguished from lentiginous nevus. Mod. Pathol., 2005, 18(10), 1397-401.
36. Keir, J. Dermatoscopic features of cutaneous non-facial non-acral lentiginous growth pattern melanomas. Dermatol. Pract. Concept, 2014, 4(1), 77-82.
37. Yonekawa, Y.; Kim, I.K.; Gragoudas, E.S.; Njauw, C.N.; Tsao, H.; Jakobiec, F.A.; Stacy, R.C. Aggressive skull base metas tasis from uveal melanoma: a clinicopathologic study. Eur. J. Ophthalmol., 2014, 24(5), 811-3.
38. Seetharamu, N.; Ott, P.A.; Pavlick, A.C. Mucosal melanomas: a case-based review of the literature. Oncologist, 2010, 15(7), 772-81.
39. Dhomen, N.; Reis-Filho, J.S.; da Rocha Dias, S.; Hayward, R.; Savage, K.; Delmas, V.; Larue, L.; Pritchard, C.; Marais, R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 2009, 15(4), 294-303.
40. Holderfield, M.; Deuker, M.M.; McCormick, F.; McMahon, M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer, 2014, 14(7), 455-67.
41. Wellbrock, C.; Karasarides, M.; Marais, R., The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol., 2004, 5(11), 875-85.
42. Dumaz, N.; Hayward, R.; Martin, J.; Ogilvie, L.; Hedley, D.; Curtin, J.A.; Bastian, B.C.; Springer, C.; Marais, R. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res., 2006, 66(19), 9483-91.
43. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature, 2002, 417(6892), 949-54.
44. Long, G.V.; Menzies, A.M.; Nagrial, A.M.; Haydu, L.E.; Hamilton, A.L.; Mann, G.J.; Hughes, T.M.; Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol., 2011, 29(10), 1239-46.
45. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature, 2007, 445(7130), 851-7.
46. Wan, P.T.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116(6), 855-67.
47. Dhomen, N.; Marais, R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev., 2007, 17(1), 31-9.
48. Sumimoto, H.; Imabayashi, F.; Iwata, T.; Kawakami, Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp.Med., 2006, 203(7), 1651-6.
49. Ackermann, J.; Frutschi, M.; Kaloulis, K.; McKee, T.; Trumpp, A.; Beermann, F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res., 2005, 65(10), 4005-11.
50. Rebecca, V.W.; Alicea, G.M.; Paraiso, K.H.; Lawrence, H.; Gibney, G.T.; Smalley, K.S. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res., 2014, 10.1111/pcmr.12303.
51. Sensi, M.; Nicolini, G.; Petti, C.; Bersani, I.; Lozupone, F.; Molla, A.; Vegetti, C.; Nonaka, D.; Mortarini, R.; Parmiani, G.; Fais, S.; Anichini, A. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene, 2006, 25(24), 3357-64.
52. Greene, V.R.; Johnson, M.M.; Grimm, E.A.; Ellerhorst, J.A. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J. Invest. Dermatol., 2009, 129(6), 1483-8.
53. Burotto, M.; Chiou, V.L.; Lee, J.M.; Kohn, E.C. The MAPK pathway across different malignancies: A new perspective. Cancer, 2014, 10.1002/cncr.28864.
54. Platz, A.; Egyhazi, S.; Ringborg, U.; Hansson, J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol. Oncol., 2008, 1(4), 395-405.
55. Posch, C.; Moslehi, H.; Feeney, L.; Green, G.A.; Ebaee, A.; Feichtenschlager, V.; Chong, K.; Peng, L.; Dimon, M.T.; Phillips, T.; Daud, A.I.; McCalmont, T.H.; LeBoit, P.E.; Ortiz-Urda, S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 2013, 110(10), 4015-20.
56. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B.J.; Anderson, D.J.; Alvarado, R.; Ludlam, M.J.; Stokoe, D.; Gloor, S.L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K.P.; Jaiswal, B.S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L.S.; Malek, S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 2010, 464(7287), 431-5.
57. Nazarian, R.; Shi, H.; Wang, Q.; Kong, X.; Koya, R.C.; Lee, H.; Chen, Z.; Lee, M.K.; Attar, N.; Sazegar, H.; Chodon, T.; Nelson, S.F.; McArthur, G.; Sosman, J.A.; Ribas, A.; Lo, R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 2010, 468(7326), 973-7.
58. Lidsky, M.; Antoun, G.; Speicher, P.; Adams, B.; Turley, R.; Augustine, C.; Tyler, D.; Ali-Osman, F. MAP kinase hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. J. Biol. Chem., 2014, 10.1074/jbc.M113.532432.
59. Omholt, K.; Platz, A.; Kanter, L.; Ringborg, U.; Hansson, J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res., 2003, 9(17), 6483-8.
60. Wong, A.K; Chin, L. An inducible melanoma model implicates a role for RAS in tumor maintenance and angiogenesis. Cancer Metastasis Rev., 2000, 19(1-2), 121-9.
61. Masaki, T.; Wang, Y.; DiGiovanna, J.J.; Khan, S.G.; Raffeld, M.; Beltaifa, S.; Hornyak, T.J.; Darling, T.N.; Lee, C.C.; Kraemer, K.H. High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients. Pigment Cell Melanoma Res., 2014, 27(3), 454-64.
62. Shull, A.Y.; Latham-Schwark, A.; Ramasamy, P.; Leskoske, K.; Oroian, D.; Birtwistle, M.R.; Buckhaults, P.J. Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One, 2012, 7(8), e43369.
63. Tsao, H.; Chin, L.; Garraway, L.A.; Fisher, D.E. Melanoma: from mutations to medicine. Genes. Dev., 2012, 26(11), 1131-55.
64. Dankort, D.; Curley, D.P.; Cartlidge, R.A.; Nelson, B.; Karnezis, A.N.; Damsky, W.E. Jr.; You, M.J.; DePinho, R.A.; McMahon, M.; Bosenberg, M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet., 2009, 41(5), 544-52.
65. Goel, V.K.; Lazar, A.J.; Warneke, C.L.; Redston, M.S.; Haluska, F.G. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol., 2006, 126(1), 154-60.
66. Nogueira, C.; Kim, K.H.; Sung, H.; Paraiso, K.H.; Dannenberg, J.H.; Bosenberg, M.; Chin, L.; Kim, M. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene, 2010, 29(47), 6222-32.
67. Marsh Durban, V.; Deuker, M.M.; Bosenberg, M.W.; Phillips, W.; McMahon, M. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J. Clin. Invest., 2013, 123(12), 5104-18.
68. Silva, J.M.; Bulman, C.; McMahon, M. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol. Cancer Res., 2014, 12(3), 447-63.
69. Vredeveld, L.C.; Possik, P.A.; Smit, M.A.; Meissl, K.; Michaloglou, C.; Horlings, H.M.; Ajouaou, A.; Kortman, P.C.; Dankort, D.; McMahon, M.; Mooi, W.J.; Peeper, D.S. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes. Dev., 2012, 26(10), 1055-69.
70. Benjamin, C.L.; Melnikova, V.O.; Ananthaswamy, H.N. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol., 2008, 624, 265-82.
71. Sarasin, A.; Dessen, P. DNA repair pathways and human metastatic malignant melanoma. Curr. Mol. Med., 2010, 10(4), 413-8.
72. Jochemsen, A.G. Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr. Opin. Oncol., 2014, 26(1), 114-9.
73. Ji, Z.; Njauw, C.N.; Taylor, M.; Neel, V.; Flaherty, K.T.; Tsao, H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J. Invest. Dermatol., 2012, 132(2), 356-64.
74. Lu, M.; Miller, P.; Lu, X. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett., 2014, 588(16), 2616-2621.
75. Hocker, T.; Tsao, H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat., 2007, 28(6), 578-88.
76. Rass, K.; Reichrath, J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol., 2008, 624, 162-78.
77. von Thaler, A.K.; Kamenisch, Y.; Berneburg, M. The role of ultraviolet radiation in melanomagenesis. Exp. Dermatol., 2010, 19(2), 81-8.
78. Dovey, M.; White, R.M.; Zon, L.I. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Zebrafish, 2009, 6(4), 397-404.
79. Shields, J.M.; Thomas, N.E.; Cregger, M.; Berger, A.J.; Leslie, M.; Torrice, C.; Hao, H.; Penland, S.; Arbiser, J.; Scott, G.; Zhou, T.; Bar-Eli, M.; Bear, J.E.; Der, C.J.; Kaufmann, W.K.; Rimm, D.L.; Sharpless, N.E. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res., 2007, 67(4), 1502-12.
80. Box, N.F.; Terzian, T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res., 2008, 21(5), 525-33.
81. Yu, H.; McDaid, R.; Lee, J.; Possik, P.; Li, L.; Kumar, S.M.; Elder, D.E.; Van Belle, P.; Gimotty, P.; Guerra, M.; Hammond, R.; Nathanson, K.L.; Dalla Palma, M.; Herlyn, M.; Xu, X. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am. J. Pathol., 2009, 174(6), 2367-77.
82. Anwar, A.; Norris, D.A.; Fujita, M. Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch. Biochem. Biophys., 2011, 508(2), 198-203.
83. Avery-Kiejda, K.A.; Bowden, N.A.; Croft, A.J.; Scurr, L.L.; Kairupan, C.F.; Ashton, K.A.; Talseth-Palmer, B.A.; Rizos, H.; Zhang, X.D.; Scott, R.J.; Hersey, P. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer, 2011, 11, 203.
84. Castellano, M.; Parmiani, G. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res., 1999, 9(5), 421-32.
85. Tsao, H.; Benoit, E.; Sober, A.J.; Thiele, C.; Haluska, F.G. Novel mutations in the p16/CDKN2A binding region of the cyclindependent kinase-4 gene. Cancer Res., 1998, 58(1), 109-13.
86. Law, M.H.; Macgregor, S.; Hayward, N.K. Melanoma genetics: recent findings take us beyond well-traveled pathways. J. Invest. Dermatol., 2012, 132(7), 1763-74.
87. Ha, L.; Merlino, G.; Sviderskaya, E.V. Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle, 2008, 7(13), 1944-8.
88. Sharpless, E.; Chin, L. The INK4a/ARF locus and melanoma. Oncogene, 2003, 22(20), 3092-8.
89. Ward, K.A.; Lazovich, D.; Hordinsky, M.K. Germline melanoma susceptibility and prognostic genes: a review of the literat ure. J. Am. Acad. Dermatol., 2012, 67(5), 1055-67.
90. Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.; Dicara, D.; Ramos, A.H.; Lawrence, M.S.; Cibulskis, K.; Sivachenko, A.; Voet, D.; Saksena, G.; Stransky, N.; Onofrio, R.C.; Winckler, W.; Ardlie, K.; Wagle, N.; Wargo, J.; Chong, K.; Morton, D.L.; Stemke-Hale, K.; Chen, G.; Noble, M.; Meyerson, M.; Ladbury, J.E.; Davies, M.A.; Gershenwald, J.E.; Wagner, S.N.; Hoon, D.S.; Schadendorf, D.; Lander, E.S.; Gabriel, S.B.; Getz, G.; Garraway, L.A.; Chin, L. A landscape of driver mutations in melanoma. Cell, 2012, 150(2), 251-63.
91. Jovanovic, B.; Egyhazi, S.; Eskandarpour, M.; Ghiorzo, P.; Palmer, J.M.; Bianchi Scarra, G.; Hayward, N.K.; Hansson, J. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J. Invest. Dermatol., 2010, 130(2), 618-20.
92. Walker, G.J.; Flores, J.F.; Glendening, J.M.; Lin, A.H.; Markl, I.D.; Fountain, J.W. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer, 1998, 22(2), 157-63.
93. Hansson, J. Familial cutaneous melanoma. Adv. Exp. Med. Biol., 2010, 685, 134-45.
94. Yakobson, E.; Shemesh, P.; Azizi, E.; Winkler, E.; Lassam, N.; Hogg, D.; Brookes, S.; Peters, G.; Lotem, M.; Zlotogorski, A.; Landau, M.; Safro, M.; Shafir, R.; Friedman, E.; Peretz, H. Two p16 (CDKN2A) germline mutations in 30 Isra eli melanoma families. Eur. J. Hum. Genet., 2000, 8(8), 590-6.
95. Taber, J.M.; Aspinwall, L.G.; Kohlmann, W.; Dow, R.; Leachman, S.A., Parental preferences for CDKN2A/p16 testing of minors. Genet. Med., 2010, 12(12), 823-38.
96. Aspinwall, L.G.; Leaf, S.L.; Dola, E.R.; Kohlmann, W.; Leachman, S.A. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol. Biomark. Prev., 2008, 17(6), 1510-9.
97. Mehnert, J.M.; Kluger, H.M. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr. Oncol. Rep., 2012, 14(5), 449-57.
98. Sheppard, K.E.; McArthur, G.A. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin. Cancer Res., 2013, 19(19), 5320-8.
99. McNeal, A.S.; Liu, K.; Nakhate, V.; Natale, C.A.; Duperret, E.K.; Capell, B.C.; Dentchev, T.; Berger, S.L.; Herlyn, M.; Seykora, J.T.; Ridky, T.W. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma. Cancer Discov., 2015, 5(10), 1072-85.
100. Afaq, F.; Katiyar, S.K. Polyphenols: skin photoprotection and inhibition of photocarcinogenesis. Mini-Rev. Med. Chem., 2011, 11(14), 1200-15.
101. Sun, Q.; Prasad, R.; Rosenthal, E.; Katiyar, S.K. Grape seed proanthocyanidins inhibit the invasive potential of head and neck cutaneous squamous cell carcinoma cells by targeting EGFR expression and epithelial-to-mesenchymal transition. BMC Compl. Altern. Med., 2011, 11, 134.
102. Vaid, M.; Prasad, R.; Sun, Q.; Katiyar, S.K. Silymarin targets beta-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS One, 2011, 6(7), e23000.
103. Strickland, L.R.; Pal, H.C. Elmets, C.A., Afaq, F. Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett., 2015, 359(1), 20-35.
104. Arai, Y.; Watanabe, S.; Kimira, M.; Shimoi, K.; Mochizuki, R.; Kinae, N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J. Nutr., 2000, 130(9), 2243-50.
105. Kimira, M.; Arai, Y.; Shimoi, K.; Watanabe, S. Japanese intake of flavonoids and isoflavonoids from foods. J. Epidemiol., 1998, 8(3), 168-75.
106. Pal, H.C.; Baxter, R.D.; Hunt, K.M.; Agarwal, J.; Elmets, C.A.; Athar, M.; Afaq, F. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF -mutated melanoma cells. Oncotarget., 2015, 6(29), 28296-311.
107. Pal, H.C.; Sharma, S.; Elmets, C.A.; Athar, M.; Afaq, F. Fisetin inhibits growth, induces G(2) /M arrest and apoptosis of human epidermoid carcinoma A431 cells: role of mitochondrial membrane potential disruption and consequent caspases activation. Exp. Dermatol., 2013, 22(7), 470-5.
108. Pal, H.C.; Sharma, S.; Strickland, L.R.; Katiyar, S.K.; Ballestas, M.E.; Athar, M.; Elmets, C.A.; Afaq, F. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFkappaB signaling pathways. PLoS One, 2014, 9(1), e86338.
109. Pal, H.C.; Athar, M.; Elmets, C.A.; Afaq, F. Fisetin inhibits UVBinduced cutaneous inflammation and activation of PI3K/AKT/ NFkappaB signaling pathways in SKH-1 hairless mice. Photochem. Photobiol., 2014, 10.1111/php.12337.
110. Pal, H.C.; Diamond, A.C.; Strickland, L.R.; Kappes, J.C.; Katiyar, S.K.; Elmets, C.A.; Athar, M.; Afaq, F. Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma. Oncotarget, 2015 Oct 26. [Epub ahead of print] PubMed PMID: 26517521.
111. Syed, D.N., Afaq, F., Maddodi, N.; Johnson, J.J.; Sarfaraz, S.; Ahmad, A.; Setaluri, V.; Mukhtar, H. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/beta-catenin signaling and decreased Mitf levels. J. Invest. Dermatol., 2011, 131(6), 1291-9.
112. Syed, D.N.; Chamcheu, J.C.; Khan, M.I.; Sechi, M.; Lall, R.K.; Adhami, V.M.; Mukhtar, H. Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling. Biochem. Pharmacol., 2014, 89(3), 349-60.
113. Ragelle, H.; Crauste-Manciet, S.; Seguin, J.; Brossard, D.; Scherman, D.; Arnaud, P.; Chabot, G.G. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int. J. Pharm., 2012, 427(2), 452-9.
114. Touil, Y.S.; Seguin, J.; Scherman, D.; Chabot, G.G. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother. Pharmacol., 2011, 68(2), 445-55.
115. Bothiraja, C.; Yojana, B.D.; Pawar, A.P.; Shaikh, K.S.; Thorat, U.H. Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study. Exp. Opin. Drug Deliv., 2014, 11(1), 17-29.
116. Seguin, J.; Brulle, L.; Boyer, R.; Lu, Y.M. Ramos Romano, M., Touil, Y.S., Scherman, D., Bessodes, M., Mignet, N., and Chabot, G.G., Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int. J. Pharm., 2013, 444(1-2), 146-54.
117. Shia, C.S.; Tsai, S.Y.; Kuo, S.C.; Hou, Y.C.; Chao, P.D. Metabolism and pharmacokinetics of 3,3',4',7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J. Agric. Food Chem., 2009, 57(1), 83-9.
118. Ichimatsu, D.; Nomura, M.; Nakamura, S.; Moritani, S.; Yokogawa, K.; Kobayashi, S.; Nishioka, T.; Miyamoto, K. Structure- activity relationship of flavonoids for inhibition of epidermal growth factorinduced transformation of JB6 Cl 41 cells. Mol. Carcinog., 2007, 46(6), 436-45.
119. Sagara, Y.; Vanhnasy, J.; Maher, P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signalregulated kinase activation. J. Neurochem., 2004, 90(5), 1144-55.
120. Akaishi, T.; Morimoto, T.; Shibao, M.; Watanabe, S.; Sakai-Kato, K.; Utsunomiya-Tate, N.; Abe, K. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein. Neurosci. Lett., 2008, 444(3), 280-5.
121. Katiyar, S.; Elmets, C.A.; Katiyar, S.K. Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair. J. Nutr. Biochem., 2007, 18(5), 287-96.
122. Katiyar, S.K.; Afaq, F.; Perez, A.; Mukhtar, H. Green tea polyphenol (-)-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogenesis, 2001, 22(2), 287-94.
123. Nandakumar, V.; Vaid, M.; Katiyar, S.K. (-)-Epigallocatechin-3- gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis, 2011, 32(4). 537-44.
124. Ravindranath, M.H.; Ramasamy, V.; Moon, S.; Ruiz, C.; Muthugounder, S. Differential growth suppression of human melanoma cells by tea (Camellia sinensis) epicatechins (ECG, EGC and EGCG). Evid. Based Complement. Altern. Med., 2009, 6(4), 523-30.
125. Nihal, M.; Ahsan, H.; Siddiqui, I.A.; Mukhtar, H.; Ahmad, N.; Wood, G.S. (-)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle, 2009, 8(13), 2057-63.
126. Nihal, M.; Roelke, C.T.; Wood, G.S. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)- epigallocatechin-3-gallate (EGCG). Pharm. Res., 2010, 27(6), 1103-14.
127. Ellis, L.Z.; Liu, W.; Luo, Y.; Okamoto, M.; Qu, D.; Dunn, J.H.; Fujita, M. Green tea polyphenol epigallocatechin -3-gallate suppresses melanoma growth by inhibiting inflammasome and IL- 1beta secretion. Biochem. Biophys. Res. Commun., 2011, 414(3), 551-6.
128. Ahmed, S.; Rahman, A.; Hasnain, A.; Lalonde, M.; Goldberg, V.M.; Haqqi, T.M. Green tea polyphenol epigallocatechin -3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic. Biol. Med., 2002, 33(8), 1097-105.
129. Shin, H.Y.; Kim, S.H.; Jeong, H.J.; Kim, S.Y.; Shin, T.Y.; Um, J.Y.; Hong, S.H.; Kim, H.M. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. Intl. Arch. Allergy Immunol., 2007, 142(4), 335-44.
130. Singh, T.; Katiyar, S.K. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS One, 2011, 6(10), e25224.
131. Chen, L.; Lee, M.J.; Li, H.; Yang, C.S. Absorption, distribution, elimination of tea polyphenols in rats. Drug Metab. Dispos., 1997, 25(9), 1045-50.
132. Langley-Evans, S.C. Consumption of black tea elicits an increase in plasma antioxidant potential in humans. Intl. J. Food Sci. Nutr., 2000, 51(5), 309-15.
133. Yashin A.N.B.; Yashin Y. Bioavailability of Tea Components. J. Food Res., 2012, 1(2), 281-290.
134. Lambert, J.D.; Lee, M.J.; Lu, H.; Meng, X.; Hong, J.J.; Seril, D.N.; Sturgill, M.G.; Yang, C.S. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J. Nutr., 2003, 133(12), 4172-7.
135. Lee, M.J.; Maliakal, P.; Chen, L.; Meng, X.; Bondoc, F.Y.; Prabhu, S.; Lambert, G.; Mohr, S.; Yang, C.S. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3- gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol. Biomark. Prev., 2002, 11(10 Pt 1), 1025-32.
136. Kale, A.; Gawande, S.; Kotwal, S.; Netke, S.; Roomi, W.; Ivanov, V.; Niedzwiecki, A.; Rath, M. Studies on the effects of oral administration of nutrient mixture, quercetin and red onions on the bioavailability of epigallocatechin gallate from green tea extract. Phytother. Res., 2010, 24 Suppl 1, S48-55.
137. Li, C.; Lee, M.J.; Sheng, S.; Meng, X.; Prabhu, S.; Winnik, B.; Huang, B.; Chung, J.Y.; Yan, S.; Ho, C.T.; Yang, C.S. Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem. Res. Toxicol., 2000, 13(3), 177-84.
138. Wiseman, S.; Mulder, T.; Rietveld, A. Tea flavonoids: bioavailability in vivo and effects on cell signaling pathways in vitro. Antioxid. Redox Signal., 2001, 3(6), 1009-21.
139. Yang, C.S.; Chen, L.; Lee, M.J.; Balentine, D.; Kuo, M.C.; Schantz, S.P. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol. Biomark. Prev., 1998, 7(4), 351-4.
140. van het Hof, K.H.; de Boer, H.S.; Wiseman, S.A.; Lien, N.; Westrate, J.A.; Tijburg, L.B. Consumption of green or black t ea does not increase resistance of low-density lipoprotein to oxidation in humans. Am. J. Clin. Nutr., 1997, 66(5), 1125-32.
141. Sun T. H.C.-T.; Shahidi F. Bioavailability and metabolism of tea catechins in human subjects. In: Tea and Tea Products. Chemistry and Health – Promoting Properties. 2009, Boca Raton, London, New York: CRC Press. Taylor and Francis Group.
142. Dryden, G.W.; Lam, A.; Beatty, K.; Qazzaz, H.H.; McClain, C.J.; A pilot study to evaluate the safety and efficacy of an oral dose of (-)- epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis. Inflamm. Bowel Dis., 2013, 19(9), 1904-12.
143. Chen, W.Y.; Hsieh, Y.A.; Tsai, C.I.; Kang, Y.F.; Chang, F.R.; Wu, Y.C.; Wu, C.C. Protoapigenone, a natural d erivative of apigenin, induces mitogen-activated protein kinase-dependent apoptosis in human breast cancer cells associated with induction of oxidative stress and inhibition of glutathione S-transferase pi. Invest. New Drugs, 2011, 29(6), 1347-59.
144. Du, G.J.; Zhang, Z.; Wen, X.D.; Yu, C.; Calway, T.; Yuan, C.S.; Wang, C.Z. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients, 2012, 4(11), 1679-91.
145. Khandelwal, A.; Hall, J.A.; Blagg, B.S. Synthesis and structureactivity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. J. Org. Chem., 2013, 78(16), 7859-84.
146. Chung, J.Y.; Huang, C.; Meng, X.; Dong, Z.; Yang, C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structureactivity relationship and mechanisms involved. Cancer Res., 1999, 59(18), 4610-7.
147. Nam, S.; Smith, D.M.; Dou, Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem., 2001, 276(16), 13322-30.
148. Wan, S.B.; Landis-Piwowar, K.R.; Kuhn, D.J.; Chen, D.; Dou, Q.P.; Chan, T.H. Structure-activity study of epi-gallocatechin gallate (EGCG) analogs as proteasome inhibitors. Bioorg. Med. Chem., 2005, 13(6), 2177-85.
149. Landis-Piwowar, K.R.; Kuhn, D.J.; Wan, S.B.; Chen, D.; Chan, T.H.; Dou, Q.P. Evaluation of proteasome-inhibitory and apoptosisinducing potencies of novel (-)-EGCG analogs and their prodrugs. Intl. J. Mol. Med., 2005, 15(4), 735-42.
150. Dodo, K.; Minato, T.; Hashimoto, Y. Structure-activity relationship of bis-galloyl derivatives related to (-)-epigallocatechin gallate. Chem. Pharm. Bull. (Tokyo), 2009, 57(2), 190-4.
151. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24(5a), 2783-840.
152. Larrosa, M.; Tomas-Barberan, F.A.; Espin, J.C. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur. J. Nutr., 2004, 43(5), 275-84.
153. Niles, R.M.; McFarland, M.; Weimer, M.B.; Redkar, A.; Fu, Y.M.; Meadows, G.G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett., 2003, 190(2), 157-63.
154. Caltagirone, S.; Rossi, C.; Poggi, A.; Ranelletti, F.O.; Natali, P.G.; Brunetti, M.; Aiello, F.B.; Piantelli, M. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Intl. J. Cancer, 2000, 87(4), 595-600.
155. Fang, Y.; Bradley, M.J.; Cook, K.M.; Herrick, E.J.; Nicholl, M.B. A potential role for resveratrol as a radiation sensitizer for melanoma treatment. J. Surg. Res., 2013, 183(2), 645-53.
156. Gatouillat, G.; Balasse, E.; Joseph-Pietras, D.; Morjani, H.; Madoulet, C. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J. Cell. Biochem., 2010, 110(4), 893-902.
157. Ivanov, V.N.; Partridge, M.A.; Johnson, G.E.; Huang, S.X.; Zhou, H.; Hei, T.K. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp. Cell. Res., 2008, 314(5), 1163-76.
158. Habibie, Yokoyama S.; Abdelhamed, S.; Awale, S.; Sakurai, H.; Hayakawa, Y.; Saiki, I. Survivin suppression through STAT3/betacatenin is essential for resveratrol-induced melanoma apoptosis. Intl. J. Oncol., 2014, 45(2), 895-901.
159. Chen, Y.J.; Chen, Y.Y.; Lin, Y.F.; Hu, H.Y.; Liao, H.F. Resveratrol inhibits alpha-melanocyte-stimulating hormone signaling, viability, and invasiveness in melanoma cells. Evid. Based Complement. Altern. Med., 2013, 2013, 632121.
160. Lee, H.; Zhang, P.; Herrmann, A.; Yang, C.; Xin, H.; Wang, Z.; Hoon, D.S.; Forman, S.J.; Jove, R.; Riggs, A.D.; Yu, H. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. USA, 2012, 109(20), 7765-9.
161. Wang, M.; Yu, T.; Zhu, C.; Sun, H.; Qiu, Y.; Zhu, X.; Li, J. Resveratrol triggers protective autophagy through the ceramide/ Akt/mTOR pathway in melanoma B16 cells. Nutr. Cancer, 2014, 66(3), 435-40.
162. Trapp, V.; Parmakhtiar, B.; Papazian, V.; Willmott, L.; Fruehauf, J.P. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis, 2010, 13(4), 305-15.
163. Chen, M.C.; Chang, W.W.; Kuan, Y.D.; Lin, S.T.; Hsu, H.C.; Lee, C.H. Resveratrol inhibits LPS-induced epithelial- mesenchymal transition in mouse melanoma model. Innate. Immun., 2012, 18(5), 685-93.
164. Asensi, M.; Medina, I.; Ortega, A.; Carretero, J.; Bano, M.C.; Obrador, E.; Estrela, J.M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med., 2002, 33(3), 387-98.
165. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.F.; Nunes, T.; Wright, L.; Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food. Res., 2009, 53 Suppl 1, S7-15.
166. Goldberg, D.M.; Yan, J.; Soleas, G.J. Absorption of three winerelated polyphenols in three different matrices by healthy subjects. Clin. Biochem., 2003, 36(1), 79-87.
167. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E. Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32(12), 1377-82.
168. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P.; Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomark. Prev., 2007, 16(6), 1246-52.
169. Burkon, A.; Somoza, V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans- resveratrol- C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res., 2008, 52(5), 549-57.
170. Boocock, D.J.; Patel, K.R.; Faust, G.E.; Normolle, D.P.; Marczylo, T.H.; Crowell, J.A.; Brenner, D.E.; Booth, T.D.; Gescher, A.; Steward, W.P. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 848(2), 182-7.
171. Larrosa, M.; Tomas-Barberan, F.A.; Espin, J.C. Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J. Agric. Food Chem., 2003, 51(16), 4576-84.
172. Murias, M.; Handler, N.; Erker, T.; Pleban, K.; Ecker, G.; Saiko, P.; Szekeres, T.; Jager, W. Resveratrol an alogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem., 2004, 12(21), 5571-8.
173. Murias, M.; Jager, W.; Handler, N.; Erker, T.; Horvath, Z.; Szekeres, T.; Nohl, H.; Gille, L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structureactivity relationship. Biochem. Pharmacol., 2005, 69(6), 903-12.
174. Lee, K.W.; Kang, N.J.; Rogozin, E.A.; Oh, S.M.; Heo, Y.S.; Pugliese, A.; Bode, A.M.; Lee, H.J.; Dong, Z. The resveratrol analogue 3,5,3',4',5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEK. Intl. J. Cancer, 2008, 123(11), 2487-96.
175. Ruweler, M.; Gulden, M.; Maser, E.; Murias, M.; Seibert, H. Cytotoxic, cytoprotective and antioxidant activities of resveratrol and analogues in C6 astroglioma cells in vitro. Chem. Biol. Interact., 2009, 182(2-3), 128-35.
176. Wachek V.H.Z.; Strommer S.; Fuereder T.; Szekeres T. Resveratrol analogue M8 chemosensitizes malignant melanoma to dacarbacin in vivo. Clin. Cancer Res., 2005, Part 2 Supply S(11), 8971S.
177. Paulitschke, V.; Schicher, N.; Szekeres, T.; Jager, W.; Elbling, L.; Riemer, A.B.; Scheiner, O.; Trimurtulu, G.; Venkateswarlu, S.; Mikula, M.; Swoboda, A.; Fiebiger, E.; Gerner, C.; Pehamberger, H.; Kunstfeld, R. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model. J. Invest. Dermatol., 2010, 130(6), 1668-79.
178. Szekeres, T.; Fritzer-Szekeres, M.; Saiko, P.; Jager, W. Resveratrol and resveratrol analogues--structure-activity relationship. Pharm. Res., 2010, 27(6), 1042-8.
179. Szekeres, T.; Saiko, P.; Fritzer-Szekeres, M.; Djavan, B.; Jager, W. Chemopreventive effects of resveratrol and resveratrol derivatives. Ann. NY Acad. Sci., 2011, 1215, 89-95.
180. Ashikawa, K.; Majumdar, S.; Banerjee, S.; Bharti, A.C.; Shishodia, S.; Aggarwal, B.B. Piceatannol inhibits TNF-induced NF- kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J. Immunol., 2002, 169(11), 6490-7.
181. Androutsopoulos, V.P.; Fragiadaki, I.; Tosca, A. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp. Dermatol., 2015, 24(8), 632-44.
182. Morris, V.L.; Toseef, T.; Nazumudeen, F.B.; Rivoira, C.; Spatafora, C.; Tringali, C.; Rotenberg, S.A. Anti-tumor properties of cisresveratrol methylated analogs in metastatic mouse melanoma cells. Mol. Cell. Biochem., 2015, 402(1-2), 83-91.
183. Sharma, R.A.; Gescher, A.J.; Steward, W.P. Curcumin: the story so far. Eur. J. Cancer, 2005, 41(13), 1955-68.
184. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14(14), 4491-9.
185. Woo, J.H.; Kim, Y.H.; Choi, Y.J.; Kim, D.G.; Lee, K.S.; Bae, J.H.; Min, D.S.; Chang, J.S.; Jeong, Y.J.; Lee, Y.H.; Park, J.W.; Kwon, T.K. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis, 2003, 24(7), 1199-208.
186. Aggarwal, S.; Ichikawa, H.; Takada, Y.; Sandur, S.K.; Shishodia, S.; Aggarwal, B.B. Curcumin (diferuloylmethane) down- regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol. Pharmacol., 2006, 69(1), 195-206.
187. Balasubramanian, S.; Eckert, R.L. Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J. Biol. Chem., 2007, 282(9), 6707-15.
188. Chen, Y.R.; Tan, T.H. Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene, 1998, 17(2), 173-8.
189. Zheng, M.; Ekmekcioglu, S.; Walch, E.T.; Tang, C.H.; Grimm, E.A. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res., 2004, 14(3), 165-71.
190. Iersel, M.L.; Ploemen, J.P.; Struik, I.; van Amersfoort, C.; Keyzer, A.E.; Schefferlie, J.G.; van Bladeren P.J. Inhibit ion of glutathione S-transferase activity in human melanoma cells by alpha,betaunsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem. Biol. Interact., 1996, 102(2), 117-32.
191. Siwak, D.R.; Shishodia, S.; Aggarwal, B.B.; Kurzrock, R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the BRaf/ mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer, 2005, 104(4), 879-90.
192. Bush, J.A.; Cheung, K.J. Jr.; Li, G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res., 2001, 271(2), 305-14.
193. Bakhshi, J.; Weinstein, L.; Poksay, K.S.; Nishinaga, B.; Bredesen, D.E.; Rao, R.V. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis, 2008, 13(7), 904-14.
194. Ray, S.; Chattopadhyay, N.; Mitra, A.; Siddiqi, M.; Chatterjee, A. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and Ecadherin. J. Environ. Pathol. Toxicol. Oncol., 2003, 22(1), 49-58.
195. Banerji, A.; Chakrabarti, J.; Mitra, A.; Chatterjee, A. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett., 2004, 211(2), 235-42.
196. Depeille, P.; Cuq, P.; Passagne, I.; Evrard, A.; Vian, L. Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br. J. Cancer, 2005, 93(2), 216-23.
197. Wu, X.; Zeng, H.; Zhang, X.; Zhao, Y.; Sha, H.; Ge, X.; Zhang, M.; Gao, X.; Xu, Q. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am. J. Pathol., 2004, 164(6), 2039-54.
198. Zeng, Q.; Dong, J.M.; Guo, K.; Li, J.; Tan, H.X.; Koh, V.; Pallen, C.J.; Manser, E.; Hong, W. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res., 2003, 63(11), 2716-22.
199. Wang, L.; Shen, Y.; Song, R.; Sun, Y.; Xu, J.; Xu, Q. An anticancer effect of curcumin mediated by down -regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol. Pharmacol., 2009, 76(6), 1238-45.
200. Philip, S.; Bulbule, A.; Kundu, G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem., 2001, 276(48), 44926-35.
201. Philip, S., Kundu, G.C. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem., 2003, 278(16), 14487-97.
202. Marin, Y.E., Wall, B.A., Wang, S., Namkoong, J., Martino, J.J., Suh, J., Lee, H.J., Rabson, A.B., Yang, C.S., Chen, S., Ryu, J.H. Curcumin downregulates the constitutive activity of NF-kappaB. induces apoptosis in novel mouse melanoma cells. Melanoma Res., 2007, 17(5), 274-83.
203. Odot, J., Albert, P., Carlier, A., Tarpin, M., Devy, J., Madoulet, C. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int. J. Cancer, 2004, 111(3), 381-7.
204. Prasad, S., Tyagi, A.K., Aggarwal, B.B. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res. Treat., 2014, 46(1), 2-18.
205. Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P.S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med., 1998, 64(4), 353-6.
206. Cheng, A.L., Hsu, C.H., Lin, J.K., Hsu, M.M., Ho, Y.F., Shen, T.S., Ko, J.Y., Lin, J.T., Lin, B.R., Ming-Shiang, W., Yu, H.S., Jee, S.H., Chen, G.S., Chen, T.M., Chen, C.A., Lai, M.K., Pu, Y.S., Pan, M.H., Wang, Y.J., Tsai, C.C., Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res., 2001, 21(4b), 2895-900.
207. Sharma, R.A., Euden, S.A., Platton, S.L., Cooke, D.N., Shafayat, A., Hewitt, H.R., Marczylo, T.H., Morgan, B., Hemingway, D., Plummer, S.M., Pirmohamed, M., Gescher, A.J., Steward, W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10(20), 6847-54.
208. Sun, J., Bi, C., Chan, H.M., Sun, S., Zhang, Q., Zheng, Y. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf B Biointerfaces, 2013, 111c, 367-375.
209. Reddy, A.R., Dinesh, P., Prabhakar, A.S., Umasankar, K., Shireesha, B., Raju, M.B. A comprehensive review on SAR of curcumin. Mini-Rev. Med. Chem., 2013, 13(12), 1769-77.
210. Vyas, A., Dandawate, P., Padhye, S., Ahmad, A., Sarkar, F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr. Pharm. Des., 2013, 19(11), 2047-69.
211. Pisano, M., Pagnan, G., Dettori, M.A., Cossu, S., Caffa, I., Sassu, I., Emionite, L., Fabbri, D., Cilli, M., Pastorino, F., Palmieri, G., Delogu, G., Ponzoni, M., Rozzo, C. Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells. Mol. Cancer, 2010, 9, 137.
212. Rozzo, C., Fanciulli, M., Fraumene, C., Corrias, A., Cubeddu, T., Sassu, I., Cossu, S., Nieddu, V., Galleri, G., Azara, E., Dettori, M.A., Fabbri, D., Palmieri, G., Pisano, M. Molecular changes induced by the curcumin analogue D6 in human melanoma cells. Mol. Cancer, 2013, 12, 37.
213. Bill, M.A., Fuchs, J.R., Li, C., Yui, J., Bakan, C., Benson, D. M, Jr., Schwartz, E.B., Abdelhamid, D., Lin, J., Hoyt, D.G., Fossey, S.L., Young, G.S., Carson, W.E., 3rd, Li, P.K., Lesinski, G.B. The small molecule curcumin analog FLLL32 induces apoptos is in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol. Cancer, 2010, 9, 165.
214. Bill, M.A., Nicholas, C., Mace, T.A., Etter, J.P., Li, C., Schwartz, E.B., Fuchs, J.R., Young, G.S., Lin, L., Lin, J., He, L., Phelps, M., Li, P.K., Lesinski, G.B. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One, 2012, 7(8), e40724.
215. Faiao-Flores, F., Suarez, J.A., Soto-Cerrato, V., Espona-Fiedler, M., Perez-Tomas, R., Maria, D.A. Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells. Tumour Biol., 2013, 34(2), 1235-43.
216. Zhang, P., Bai, H., Liu, G., Wang, H., Chen, F., Zhang, B., Zeng, P., Wu, C., Peng, C., Huang, C., Song, Y., Song, E. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2. Toxicol. Lett., 2015, 234(3), 151-61.
217. Li, W.G., Zhang, X.Y., Wu, Y.J., Tian, X. Anti-inflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol. Sin., 2001, 22(12), 1117-20.
218. Martinez, C., Vicente, V., Yanez, J., Alcaraz, M., Castells, M.T., Canteras, M., Benavente-Garcia, O., Castillo, J. The effect of the flavonoid diosmin, grape seed extract and red wine on the pulmonary metastatic B16F10 melanoma. Histol. Histopathol., 2005, 20(4), 1121-9.
219. Mittal, A., Elmets, C.A., Katiyar, S.K. Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis, 2003, 24(8), 1379-88.
220. Tatsuno, T., Jinno, M., Arima, Y., Kawabata, T., Hasegawa, T., Yahagi, N., Takano, F., Ohta, T. Anti-inflammatory and antimelanogenic proanthocyanidin oligomers from peanut skin. Biol. Pharm. Bull., 2012, 35(6), 909-16.
221. Vaid, M., Singh, T., Katiyar, S.K. Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition. PLoS One, 2011, 6(6), e21539.
222. Martinez Conesa, C., Vicente Ortega, V., Yanez Gascon, M.J., Garcia Reverte, J.M., Canteras Jordana, M., Alcaraz Banos, M.; [Experimental model for treating pulmonary metastatic melanoma using grape-seed extract, red wine and ethanol]. Clin. Transl. Oncol., 2005, 7(3), 115-21.
223. Gu, L., Kelm, M.A., Hammerstone, J.F., Beecher, G., Holden, J., Haytowitz, D., Gebhardt, S., Prior, R.L. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. J. Nutr., 2004, 134(3), p. 613-7.
224. Stoupi, S., Williamson, G., Viton, F., Barron, D., King, L.J., Brown, J.E., Clifford, M.N., In vivo bioavailability, absorption, excretion, and pharmacokinetics of [14C]procyanidin B2 in male rats. Drug Metab. Dispos., 2010, 38(2), 287-91.
225. Choy, Y.Y., Jaggers, G.K., Oteiza, P.I., Waterhouse, A.L. Bioavailability of intact proanthocyanidins in the rat colon after ingestion of grape seed extract. J. Agric. Food Chem., 2013, 61(1), 121-7.
226. Shoji, T., Masumoto, S., Moriichi, N., Akiyama, H., Kanda, T., Ohtake, Y., Goda, Y. Apple procyanidin oligomers absorption in rats after oral administration: analysis of procyanidins in plasma using the porter method and high-performance liquid chromatography/tandem mass spectrometry. J. Agric. Food Chem., 2006, 54(3), 884-92.
227. Deprez, S., Brezillon, C., Rabot, S., Philippe, C., Mila, I., Lapierre, C., Scalbert, A. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. J. Nutr., 2000, 130(11), 2733-8.
228. Appeldoorn, M.M., Vincken, J.P., Aura, A.M., Hollman, P.C., Gruppen, H. Procyanidin dimers are metabolized by human microbiota with 2-(3,4-dihydroxyphenyl)acetic acid and 5-(3,4-dihydroxyphenyl)-gamma-valerolactone as the major metabolites. J. Agric. Food Chem., 2009, 57(3), 1084-92.
229. Manach, C., Williamson, G., Morand, C., Scalbert, A., Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 2005, 81(1 Suppl): 230s-242s.
230. Tsang, C., Auger, C., Mullen, W., Bornet, A., Rouanet, J.M., Crozier, A., Teissedre, P.L. The absorption, metabolism and excretion of flavan-3-ols and procyanidins following the ingestion of a grape seed extract by rats. Br. J. Nutr., 2005, 94(2), 170-81.
231. Kashiwada, Y., Nonaka, G., Nishioka, I., Chang, J.J., Lee, K.H. Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents. J. Nat. Prod., 1992, 55(8), 1033-43.
232. Kolodziej H H.C., Woerdenbag H.J., Konings, A.W.T. Moderate cytotoxicity of proanthocyanidins to human tumour cell lines. Phytother. Res., 1995, 9, 410-415.
233. Kozikowski, A.P., Tuckmantel, W., George, C. Studies in polyphenol chemistry and bioactivity. 2. Establishment of interflavan linkage regio-and stereochemistry by oxidative degradation of an O-alkylated derivative of procyanidin B2 to (R)-(-)-2,4-diphenylbutyric acid. J. Org. Chem., 2000, 65(17), 5371-81.
234. Kozikowski, A.P., Tuckmantel, W., Bottcher, G., Romanczyk, L.J. Jr., Studies in polyphenol chemistry and bioactivity. 4.(1) Synthesis of trimeric, tetrameric, pentameric, and higher oligomeric epicatechin-derived procyanidins having all-4beta,8-interflavan connectivity and their inhibition of cancer cell growth through cell cycle arrest. J. Org. Chem., 2003, 68(5), 1641-58.
235. Fujii, W., Toda, K., Kawaguchi, K., Kawahara, S.I., Katoh, M., Hattori, Y., Fujii, H., Makabe, H. Syntheses of prodelphinidi n B3 and C2, and their antitumor activities through cell cycle arrest and caspase-3 activation. Tetrahedron, 2013, 69, 3543-50.
236. Duan, L., Carrier, D.J., Clausen, E.C. Silymarin extraction from milk thistle using hot water. Appl. Biochem. Biotechnol., 2004, 113 116, 559-68.
237. Wallace, S.N., Carrier, D.J., Clausen, E. Extraction of nutraceuticals from milk thistle: part II. Extraction with organic solvents. Appl. Biochem. Biotechnol., 2003, 105 108, 891-903.
238. Wagner, H., Horhammer, L., Munster, R. [On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.)]. Arzneimittelforschung, 1968, 18(6), 688-96.
239. Katiyar, S.K. Silymarin and skin cancer prevention: antiinflammatory, antioxidant and immunomodulatory effects (Review). Int. J. Oncol., 2005, 26(1), 169-76.
240. Katiyar, S.K., Korman, N.J., Mukhtar, H., Agarwal, R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J. Natl. Cancer Inst., 1997, 89(8), 556-66.
241. Agarwal, R., Agarwal, C., Ichikawa, H., Singh, R.P., Aggarwal, B.B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res., 2006, 26(6b), 4457-98.
242. Singh, R.P., Agarwal, R. Flavonoid antioxidant silymarin and skin cancer. Antioxid. Redox Signal., 2002, 4(4), 655-63.
243. Lee, M.H., Huang, Z., Kim, D.J., Kim, S.H., Kim, M.O., Lee, S.Y., Xie, H., Park, S.J., Kim, J.Y., Kundu, J.K., Bode, A.M., Surh, Y.J., Dong, Z. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev. Res. (Phila), 2013, 6(5), 455-65.
244. Li, L.H., Wu, L.J., Jiang, Y.Y., Tashiro, S., Onodera, S., Uchiumi, F., Ikejima, T. Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells. J. Asian. Nat. Prod. Res., 2007, 9(6 8), 593-602.
245. Schandalik, R; Perucca, E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp. Clin. Res., 1994, 20(1), 37-42.
246. Schandalik, R., Gatti, G., Perucca, E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung, 1992, 42(7), 964-8.
247. Weyhenmeyer, R., Mascher, H., Birkmayer, J. Study on doselinearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol., 1992, 30(4), 134-8.
248. Lorenz, D., Lucker, P.W., Mennicke, W.H., Wetzelsberger, N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find. Exp. Clin. Pharmacol., 1984, 6(10), 655-61.
249. Ahmed, B., Khan, S.A., Alam, T. Synthesis and antihepatotoxic activity of some heterocyclic compounds containing the 1,4 -dioxane ring system. Pharmazie, 2003, 58(3), 173-6.
250. Agarwal, C., Wadhwa, R., Deep, G., Biedermann, D., Gazak, R., Kren, V., Agarwal, R. Anti-cancer efficacy of silybin derivatives --a structure-activity relationship. PLoS One, 2013, 8(3), e60074.
251. Patel, D., Shukla, S., Gupta, S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int. J. Oncol., 2007, 30(1), 233-45.
252. Chao, S.C., Huang, S.C., Hu, D.N., Lin, H.Y. Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways. Evid. Based Complement. Alternat. Med., 2013, 2013, 817674.
253. Ye, Y., Chou, G.X., Wang, H., Chu, J.H., Yu, Z.L. Flavonoids, apigenin and icariin exert potent melanogenic activities in murine B16 melanoma cells. Phytomedicine, 2010, 18(1), 32-5.
254. Piantelli, M., Rossi, C., Iezzi, M., La Sorda, R., Iacobelli, S., Alberti, S., Natali, P.G. Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. J. Cell Physiol., 2006, 207(1), 23-9.
255. Das, S., Das, J., Samadder, A., Boujedaini, N., Khuda-Bukhsh, A.R. Apigenin-induced apoptosis in A375 and A549 cells through selective action and dysfunction of mitochondria. Exp. Biol. Med. (Maywood), 2012, 237(12), 1433-48.
256. Das, S., Das, J., Samadder, A., Paul, A., Khuda-Bukhsh, A.R. Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro. Toxicol. Lett., 2013, 223(2), 124-38.
257. Ross, J.A., Kasum, C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu. Rev. Nutr., 2002, 22, 19-34.
258. Zhang, J., Liu, D., Huang, Y., Gao, Y., Qian, S. Biopharmaceutics classification and intestinal absorption study of apigenin. Int. J. Pharm., 2012, 436(1 2), 311-7.
259. Gradolatto, A., Basly, J.P., Berges, R., Teyssier, C., Chagnon, M.C., Siess, M.H., Canivenc-Lavier, M.C. Pharmacokinetics and metabolism of apigenin in female and male rats after a single oral administration. Drug Metab. Dispos., 2005, 33(1), 49-54.
260. Hanske, L., Loh, G., Sczesny, S., Blaut, M., Braune, A. The bioavailability of apigenin-7-glucoside is influenced by human intestinal microbiota in rats. J. Nutr., 2009, 139(6), 1095-102.
261. Meyer, H., Bolarinwa, A., Wolfram, G., Linseisen, J. Bioavailability of apigenin from apiin-rich parsley in humans. Ann. Nutr. Metab., 2006, 50(3), 167-72.
262. Ding, S.M., Zhang, Z.H., Song, J., Cheng, X.D., Jiang, J., Jia, X.B. Enhanced bioavailability of apigenin via preparation of a carbon nanopowder solid dispersion. Int. J. Nanomed., 2014, 9, 2327-33.
263. Chang, H.L., Su, J.H., Yeh, Y.T., Lee, Y.C., Chen, H.M., Wu, Y.C., Yuan, S.S. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo. Cancer Lett., 2008, 267(1), 85-95.
264. Chang, H.L., Wu, Y.C., Su, J.H., Yeh, Y.T., Yuan, S.S. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2. J. Pharmacol. Exp. Ther., 2008, 325(3), 841-9.
265. Hunyadi, A., Chuang, D.W., Danko, B., Chiang, M.Y., Lee, C.L., Wang, H.C., Wu, C.C., Chang, F.R., Wu, Y.C. Direct semisynthesis of the anticancer lead-drug protoapigenone from apigenin, and synthesis of further new cytotoxic protoflavone derivatives. PLoS One, 2011, 6(8), e23922.
266. Zheng, X., Yu, L., Yang, J., Yao, X., Yan, W., Bo, S., Liu, Y., Wei, Y., Wu, Z., Wang, G. Synthesis and Anti -cancer Activities of Apigenin Derivatives. Med. Chem., 2014.
267. Liu, R., Zhao, B., Wang, D.E., Yao, T., Pang, L., Tu, Q., Ahmed, S.M., Liu, J.J., Wang, J. Nitrogen-containing apigenin analogs: preparation and biological activity. Molecules, 2012, 17(12), 14748-64.
268. Shin, D.H., Kim, O.H., Jun, H.S., Kang, M.K. Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the phosphatidylinositol 3-kinase/Akt/Rac1 signal pathway. Exp. Mol. Med., 2008, 40(5), 486-94.
269. Surh, Y.J., Lee, E., Lee, J.M. Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutat. Res., 1998, 402(1 2), 259-67.
270. Kim, M.Y. Nitric oxide triggers apoptosis in A375 human melanoma cells treated with capsaicin and resveratrol. Mol. Med. Rep., 2012, 5(2), 585-91.
271. Patel, P.S., Varney, M.L., Dave, B.J., Singh, R.K. Regulation of constitutive and induced NF-kappaB activation in malignant melanoma cells by capsaicin modulates interleukin-8 production and cell proliferation. J. Interferon. Cytokine Res., 2002, 22(4), 427-35.
272. Patel, P.S., Yang, S., Li, A., Varney, M.L., Singh, R.K. Capsaicin regulates vascular endothelial cell growth factor expression by modulation of hypoxia inducing factor-1alpha in human malignant melanoma cells. J. Cancer Res. Clin. Oncol., 2002, 128(9), 461-8.
273. Morre, D.J., Sun, E., Geilen, C., Wu, L.Y., de Cabo, R., Krasagakis, K., Orfanos, C.E., Morre, D.M. Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines. Eur. J. Cancer, 1996, 32a(11), 1995-2003.
274. Min, J.K., Han, K.Y., Kim, E.C., Kim, Y.M., Lee, S.W., Kim, O.H., Kim, K.W., Gho, Y.S., Kwon, Y.G. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res., 2004, 64(2), 644-51.
275. Beaudry, F., Vachon, P. Quantitative determination of capsaicin, a transient receptor potential channel vanilloid 1 agonist, by liquid chromatography quadrupole ion trap mass spectrometry: evaluation of in vitro metabolic stability. Biomed. Chromatogr., 2009, 23(2), 204-11.
276. Chanda, S., Bashir, M., Babbar, S., Koganti, A., Bley, K. In vitro hepatic and skin metabolism of capsaicin. Drug Metab. Dispos., 2008, 36(4), 670-5.
277. Appendino, G., Harrison, S., De Petrocellis, L., Dadd ario, N., Bianchi, F., Schiano Moriello, A., Trevisani, M., Benvenuti, F., Geppetti, P., Di Marzo, V. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Br. J. Pharmacol., 2003, 139(8), 1417-24.
278. Yang, D., Luo, Z., Ma, S., Wong, W.T., Ma, L., Zhong, J., He, H., Zhao, Z., Cao, T., Yan, Z., Liu, D., Arendshorst, W.J., Hua ng, Y., Tepel, M., Zhu, Z. Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab., 2010, 12(2), 130-41.
279. Chaiyasit, K., Khovidhunkit, W., Wittayalertpanya, S. Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J. Med. Assoc. Thai., 2009, 92(1), 108-13.
280. Suresh, D., Srinivasan, K. Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. Indian J. Med. Res., 2010, 131, 682-91.
281. William Rollyson, C.S., Brown, K., Perry, H., Stevenson, C., Crabtree, C., Dom, A., Lau, J., Witte, T., Hardman, W., Dasgupta, P. The anti-cancer dietary compound capsaicin shows higher bioavailability in the lung than other organs. FASEB J., 2014, 1(28), S644.2.
282. Walpole, C.S., Bevan, S., Bovermann, G., Boelsterli, J.J., Breckenridge, R., Davies, J.W., Hughes, G.A., James, I., Oberer, L., Winter, J., et al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J. Med. Chem., 1994, 37(13), 1942-54.
283. Walpole, C.S., Wrigglesworth, R., Bevan, S., Campbell, E.A., Dray, A., James, I.F., Masdin, K.J., Perkins, M.N., Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 3. The hydrophobic side-chain "Cregion". J. Med. Chem., 1993, 36(16), 2381-9.
284. Walpole, C.S., Wrigglesworth, R., Bevan, S., Campbell, E.A., Dray, A., James, I.F., Masdin, K.J., Perkins, M.N., Winter, J. Analogues of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond "B-region". J. Med. Chem., 1993, 36(16), 2373-80.
285. Walpole, C.S., Wrigglesworth, R., Bevan, S., Campbell, E.A., Dray, A., James, I.F., Perkins, M.N., Reid, D.J., Winter, J., Analogues of capsaicin with agonist activity as novel analgesic agents; structureactivity studies. 1. The aromatic "A-region". J. Med. Chem., 1993, 36(16), 2362-72.
286. Huang, X.F., Xue, J.Y., Jiang, A.Q., Zhu, H.L. Capsaicin and its analogues: structure-activity relationship study. Curr. Med. Chem., 2013, 20(21), 2661-72.
287. Thomas, K.C., Ethirajan, M., Shahrokh, K., Sun, H., Lee, J., Cheatham, T.E., 3rd, Yost, G.S., Reilly, C.A. Structure-activity relationship of capsaicin analogs and transient receptor potential vanilloid 1-mediated human lung epithelial cell toxicity. J. Pharmacol. Exp. Ther., 2011, 337(2), 400-10.
288. Cong, R., Sun, Q., Yang, L., Gu, H., Zeng, Y., Wang, B. Effect of Genistein on vasculogenic mimicry formation by human u veal melanoma cells. J. Exp. Clin. Cancer Res., 2009, 28, 124.
289. Danciu, C., Borcan, F., Bojin, F., Zupko, I., Dehelean, C. Effect of the isoflavone genistein on tumor size, metastasis potential and melanization in a B16 mouse model of murine melanoma. Nat. Prod. Commun., 2013, 8(3), 343-6.
290. Kiguchi, K., Constantinou, A.I., Huberman, E. Genistein-induced cell differentiation and protein-linked DNA strand breakage in human melanoma cells. Cancer Commun., 1990, 2(8), 271-7.
291. Sjoberg, E.R., Chammas, R., Ozawa, H., Kawashima, I., Khoo, K.H., Morris, H.R., Dell, A., Tai, T., Varki, A. Expression of de-N-acetyl-gangliosides in human melanoma cells is induced by genistein or nocodazole. J. Biol. Chem., 1995, 270(7), 2921-30.
292. Ji, C., Yang, Y.L., He, L., Gu, B., Xia, J.P., Sun, W.L., Su, Z.L., Chen, B., Bi, Z.G. Increasing ceramides sensitizes genisteininduced melanoma cell apoptosis and growth inhibition. Biochem. Biophys. Res. Commun., 2012, 421(3), 462-7.
293. Yang, Y., Wang, H., Wang, J., Li, X., Ma, M., Yang, W. [Effect of livin gene suppression by genistein on apoptosis, cell cycle and proliferation of malignant melanoma LiBr cells]. Nan Fang Yi Ke Da Xue Xue Bao, 2012, 32(8), 1163-7.
294. Casagrande, F., Darbon, J.M. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp. Cell Res., 2000, 258(1), 101-8.
295. Darbon, J.M., Penary, M., Escalas, N., Casagrande, F., Goubin-Gramatica, F., Baudouin, C., Ducommun, B. Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells. J. Biol. Chem., 2000, 275(20),15363-9.
296. Kuzumaki, T., Kobayashi, T., Ishikawa, K. Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun., 1998, 251(1), 291-5.
297. Rauth, S., Kichina, J., Green, A. Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. Br. J. Cancer, 1997, 75(11), 1559-66.
298. Menon, L.G., Kuttan, R., Nair, M.G., Chang, Y.C., Kuttan, G. Effect of isoflavones genistein and daidzein in the inhibit ion of lung metastasis in mice induced by B16F-10 melanoma cells. Nutr. Cancer, 1998, 30(1), 74-7.
299. Yan, C., Han, R. Suppression of adhesion-induced protein tyrosine phosphorylation decreases invasive and metastatic potentials of B16-BL6 melanoma cells by protein tyrosine kinase inhibitor genistein. Invasion Metastasis, 1997, 17(4), 189-98.
300. Yan, C., Han, R. Genistein suppresses adhesion-induced protein tyrosine phosphorylation and invasion of B16-BL6 melanoma cells. Cancer Lett, 1998, 129(1), 117-24.
301. Farina, H.G., Pomies, M., Alonso, D.F., Gomez, D.E. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol. Rep., 2006, 16(4), 885-91.
302. Record, I.R., Broadbent, J.L., King, R.A., Dreosti, I.E., Head, R.J., Tonkin, A.L. Genistein inhibits growth of B16 melanoma cells in vivo and in vitro and promotes differentiation in vitro. Int. J. Cancer, 1997, 72(5), 860-4.
303. Wang, Y., Catana, F., Yang, Y., Roderick, R., van Breemen, R.B. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J.Agric. Food Chem., 2002, 50(3), 431-5.
304. Yan, C.H., Chen, X.G., Li, Y., Han, R. Effects of genistein, a soybean-derived isoflavone, on proliferation and differentiation of B16-BL6 mouse melanoma cells. J. Asian Nat. Prod. Res., 1999, 1(4), 285-99.
305. Cohen, R., Schwartz, B., Peri, I., Shimoni, E. Improving bioavailability and stability of genistein by complexation with highamylose corn starch. J. Agric. Food Chem., 2011, 59(14), 7932-8.
306. Zhou, P., Li, L.P., Luo, S.Q., Jiang, H.D., Zeng, S. Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J. Agric. Food Chem., 2008, 56(1), 296-300.
307. Coldham, N.G., Zhang, A.Q., Key, P., Sauer, M.J. Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity. Eur. J. Drug Metab. Pharmacokinet., 2002, 27(4), 249-58.
308. Steensma, A., Faassen-Peters, M.A., Noteborn, H.P., Rietjens, I.M. Bioavailability of genistein and its glycoside genistin as measured in the portal vein of freely moving unanesthetized rats. J. Agric. Food Chem., 2006, 54(21), 8006-12.
309. Kwon, S.H., Kang, M.J., Huh, J.S., Ha, K.W., Lee, J.R., Lee, S.K., Lee, B.S., Han, I.H., Lee, M.S., Lee, M.W., Lee, J., Choi, Y.W., Comparison of oral bioavailability of genistein and genistin in rats. Int. J. Pharm., 2007, 337(1 2), 148-54.
310. Kim, K.H., Dodsworth, C., Paras, A., Burton, B.K. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol. Genet. Metab., 2013, 109(4), 382-5.
311. Setchell, K.D., Brown, N.M., Desai, P., Zimmer-Nechemias, L., Wolfe, B.E., Brashear, W.T., Kirschner, A.S., Cassidy, A., Heubi, J.E. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J. Nutr., 2001, 131(4 Suppl), 1362s-75s.
312. Ullmann, U., Oberwittle, H., Grossmann, M., Riegger, C. Repeated oral once daily intake of increasing doses of the novel synthetic genistein product Bonistein in healthy volunteers. Planta Med., 2005, 71(10), 891-6.
313. Rusin, A., Krawczyk, Z., Grynkiewicz, G., Gogler, A., Zawisza-Puchalka, J., Szeja, W. Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim. Pol., 2010, 57(1).
314. Ullah, M.F., Shamim, U., Hanif, S., Azmi, A.S., Hadi, S.M. Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Mol. Nutr. Food Res., 2009, 53(11), 1376-85.
315. Byczek, A. J. Z.-P., Gruca, A., Papaj, K., Grynkiewicz, G., Rusin, M., Szeja, W., Rusin, A. Genistein Derivatives Regioisomerically Substituted at 7-O-and 4'-O-Have Different Effect on the Cell Cycle. J.Chem., 2013.
316. Li, Q.S., Li, C.Y., Li, Z.L., Zhu, H.L. Genistein and its synthetic analogs as anticancer agents. Anticancer Agents Med. Chem., 2012, 12(3), 271-81.
317. Polkowski, K., Popiolkiewicz, J., Krzeczynski, P., Ramza, J., Pucko, W., Zegrocka-Stendel, O., Boryski, J., Skierski, J.S., Mazurek, A.P., Grynkiewicz, G. Cytostatic and cytotoxic activity of synthetic genistein glycosides against human cancer cell lines. Cancer Lett., 2004, 203(1), 59-69.
318. Rusin, A., Gogler, A., Glowala-Kosinska, M., Bochenek, D., Gruca, A., Grynkiewicz, G., Zawisza, J., Szeja, W., Krawczyk, Z. Unsaturated genistein disaccharide glycoside as a novel agent affecting microtubules. Bioorg. Med. Chem. Lett., 2009, 19(17), 4939-43.
319. Rusin, A., Zawisza-Puchalka, J., Kujawa, K., Gogler-Piglowska, A., Wietrzyk, J., Switalska, M., Glowala-Kosinska, M., Gruca, A., Szeja, W., Krawczyk, Z., Grynkiewicz, G. Synthetic conjugates of genistein affecting proliferation and mitosis of cancer cells. Bioorg. Med. Chem., 2011, 19(1), 295-305.
320. Rusin, A. M.C., Papaj, K., Grynkiewicz, G., Szeja, W. CGlycosidic genistein conjugates and their antiproliferative activity. J. Chem., 2013, 14.
321. Gogler-Piglowska, A., Rusin, A., Bochenek, D., Krawczyk, Z. Aneugenic effects of the genistein glycosidic derivative substituted at C7 with the unsaturated disaccharide. Cell. Biol. Toxicol., 2012, 28(5), 331-42.
322. Aggarwal, B.B., Ichikawa, H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle, 2005, 4(9), 1201-15.
323. Safe, S., Papineni, S., Chintharlapalli, S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett., 2008, 269(2), 326-38.
324. Weng, J.R., Tsai, C.H., Kulp, S.K., Wang, D., Lin, C.H., Yang, H.C., Ma, Y., Sargeant, A., Chiu, C.F., Tsai, M.H., Chen, C.S. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Res., 2007, 67(16), 7815-24.
325. Kim, D.S., Jeong, Y.M., Moon, S.I., Kim, S.Y., Kwon, S.B., Park, E.S., Youn, S.W., Park, K.C. Indole-3-carbinol enhances ultraviolet B-induced apoptosis by sensitizing human melanoma cells. Cell Mol. Life Sci., 2006, 63(22), 2661-8.
326. Kim, S.Y., Kima, D.S., Jeong, Y.M., Moon, S.I., Kwon, S.B., Park, K.C. Indole-3-carbinol and ultraviolet B induce apoptosis of human melanoma cells via down-regulation of MITF. Pharmazie, 2011, 66(12), 982-7.
327. Aronchik, I., Kundu, A., Quirit, J.G., Firestone, G.L. The Antiproliferative Response of Indole-3-carbinol in human melanoma cells is Triggered by an Interaction with NEDD4-1 and Disruption of Wild-type PTEN Degradation. Mol. Cancer Res., 2014, 10.1158/1541-7786.mcr-14-0018.
328. Christensen, J.G., LeBlanc, G.A. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol. Cancer Res., 1996, 56(3), 574-81.
329. Leibelt, D.A., Hedstrom, O.R., Fischer, K.A., Pereira, C.B., Williams, D.E. Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3'-diindolylmethane in spraguedawley rats. Toxicol. Sci., 2003, 74(1), 10-21.
330. Reed, G.A., Arneson, D.W., Putnam, W.C., Smith, H.J., Gray, J.C., Sullivan, D.K., Mayo, M.S., Crowell, J.A., Hurwitz, A. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol. Biomarkers Prev., 2006, 15(12), 2477-81.
331. Chintharlapalli, S., Papineni, S., Baek, S.J., Liu, S., Safe, S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal antiinflammatory drug-activated gene-1. Mol. Pharmacol., 2005, 68(6), 1782-92.
332. Chintharlapalli, S., Smith, R., 3rd, Samudio, I., Zhang, W., Safe, S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Res., 2004, 64(17), 5994-6001.
333. Contractor, R., Samudio, I.J., Estrov, Z., Harris, D., McCubrey, J.A., Safe, S.H., Andreeff, M., Konopleva, M. A novel ringsubstituted diindolylmethane,1,1-bis [3'-(5-methoxyindolyl)]-1-(p-tbutylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res., 2005, 65(7), 2890-8.
334. Kassouf, W., Chintharlapalli, S., Abdelrahim, M., Nelkin, G., Safe, S., Kamat, A.M. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res., 2006, 66(1), 412-8.
335. Qin, C., Morrow, D., Stewart, J., Spencer, K., Porter, W., Smith, R., 3rd, Phillips, T., Abdelrahim, M., Samudio, I., Safe, S. A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes. Mol. Cancer Ther., 2004, 3(3), 247-60.
336. Jong L C.W. Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents, U.S., Editor. 2004.
337. Jong L C.W. Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents, U.S., Editor. 2006.
338. Brandi, G., Paiardini, M., Cervasi, B., Fiorucci, C., Filippone, P., De Marco, C., Zaffaroni, N., Magnani, M.A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res., 2003, 63(14), 4028-36.
339. Weng, J.R., Omar, H.A., Kulp, S.K., Chen, C.S. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini-Rev. Med. Chem., 2010, 10(5), 398-404.
340. Jump, S.M., Kung, J., Staub, R., Kinseth, M.A., Cram, E.J., Yudina, L.N., Preobrazhenskaya, M.N., Bjeldanes, L.F., and Firest one, G.L., N-Alkoxy derivatization of indole-3-carbinol increases the efficacy of the G1 cell cycle arrest and of I3C-specific regulation of cell cycle gene transcription and activity in human breast cancer cells. Biochem Pharmacol, 2008. 75(3), 713-24.
341. Nguyen, H.H., Lavrenov, S.N., Sundar, S.N., Nguyen, D.H., Tseng, M., Marconett, C.N., Kung, J., Staub, R.E., Preobrazhenskaya, M.N., Bjeldanes, L.F., Firestone, G.L. 1-Benzyl-indole-3-carbinol is a novel indole-3-carbinol derivative with significantly enhanced potency of anti-proliferative and anti-estrogenic properties in human breast cancer cells. Chem. Biol. Interact., 2010, 186(3), 255-66.
342. Lopez-Lazaro, M. Distribution and biological activities of the flavonoid luteolin. Mini-Rev. Med. Chem., 2009, 9(1), 31-59.
343. Horibe, I., Satoh, Y., Shiota, Y., Kumagai, A., Horike, N., Takemori, H., Uesato, S., Sugie, S., Obata, K., Kawahara, H., Nagaoka, Y. Induction of melanogenesis by 4'-O-methylated flavonoids in B16F10 melanoma cells. J. Nat. Med., 2013, 67(4), 705-10.
344. Choi, M.Y., Song, H.S., Hur, H.S., Sim, S.S. Whitening activity of luteolin related to the inhibition of cAMP pathway in alpha-MSHstimulated B16 melanoma cells. Arch. Pharm. Res., 2008, 31(9), 1166-71.
345. Ruan, J.S., Liu, Y.P., Zhang, L., Yan, L.G., Fan, F.T., Shen, C.S., Wang, A.Y., Zheng, S.Z., Wang, S.M., Lu, Y. Luteolin reduce s the invasive potential of malignant melanoma cells by targeting beta3 integrin and the epithelial-mesenchymal transition. Acta Pharmacol. Sin., 2012, 33(10), 1325-31.
346. Casagrande, F., Darbon, J.M. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem. Pharmacol., 2001, 61(10), 1205-15.
347. George, V.C., Naveen Kumar, D.R., Suresh, P.K., Kumar, S., Kumar, R.A. Comparative studies to evaluate relative in vitro potency of luteolin in inducing cell cycle arrest and apoptosis in HaCaT and A375 cells. Asian Pac. J. Cancer Prev., 2013, 14(2), 631-7.
348. Horvathova, K., Chalupa, I., Sebova, L., Tothova, D., Vachalkova, A. Protective effect of quercetin and luteolin in human melanoma HMB-2 cells. Mutat. Res., 2005, 565(2), 105-12.
349. Iwashita, K., Kobori, M., Yamaki, K., Tsushida, T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci. Biotechnol. Biochem., 2000, 64(9), 1813-20.
350. Nakashima, S., Matsuda, H., Oda, Y., Nakamura, S., Xu, F., Yoshikawa, M. Melanogenesis inhibitors from the desert plant Anastatica hierochuntica in B16 melanoma cells. Bioorg. Med. Chem., 2010, 18(6), 2337-45.
351. Shimoi, K., Okada, H., Furugori, M., Goda, T., Takase, S., Suzuki, M., Hara, Y., Yamamoto, H., Kinae, N. Intestinal abs orption of luteolin and luteolin 7-O-beta-glucoside in rats and humans. FEBS Lett., 1998, 438(3), 220-4.
352. Cheng, L., Tan, H., Wu, X., Hu, R., Aw, C., Zhao, M., Shen, H.M., Lu, Y. Novel synthetic luteolin analogue-caused sensitization of tumor necrosis factor-alpha-induced apoptosis in human tumor cells. Org. Biomol. Chem., 2008, 6(22), 4102-4.